N. Muszbek - Concepedia

Author

N. Muszbek

EVRAZ (United Kingdom)ORCID

Also Known As

N Muszbek, N. Muszbek, Noemi Muszbek, Noémi Muszbek

Publications

Citations

H-Index

Concepts

All Affiliations

EVRAZ (United Kingdom)United BioSource Corporation (United Kingdom)Sanofi (France)

About

N. Muszbek is an author at EVRAZ (United Kingdom) specializing in public health, health policy, and health economics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Public Health	4	4	125
2	Health Policy	4	4	125
3	Health Economics	4	4	125
4	Medicine	3	3	100
5	Health Care Finance	1	1	31

N. Muszbek

Publications

210

Citations

H-Index

Page 1

	Year	Citations
Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards Ágota Szende, Zsolt Mogyorósy, N. Muszbek, The European Journal of Health Economics Primary CareHealth System AnalysisMethodological GuidelinesHealth PolicyHealth Economics	2002	57
Does therapeutic reference pricing always result in cost-containment? Zoltán Kaló, N. Muszbek, József Bodrogi, Health Policy Health PolicyHealth EconomicsPharmacoeconomicsCost EffectivenessHealth Care Finance	2006	31
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada N. Muszbek, Sonalee Shah, Stuart Carroll, Current Medical Research and Opinion	2008	29
Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands Dara Stein, Florence Joulain, Sarah Naoshy, International Journal of Colorectal Disease Healthcare ValueHealth EconomicsHealth PolicyColorectal CancerPatient-reported Outcome	2014	25
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs N. Muszbek, Clare Proudfoot, Marie Fournier, Advances in Therapy	2019	13
Public health value of fixed‐dose combinations in hypertension Luís M. Ruilope, Michel Burnier, N. Muszbek, Blood Pressure HypertensionCardiovascular PharmacologyPharmacotherapyBlood PressureThrombosis	2008	12
Cost–Utility Analysis of Selective Internal Radiation Therapy with Y-90 Resin Microspheres in Hepatocellular Carcinoma N. Muszbek, Edit Remák, Rachel Evans, Future Oncology	2020	12
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma N. Muszbek, Ananth Kadambi, Tereza Lanitis, Clinical Therapeutics	2016	11
Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin Chantelle Browne, N. Muszbek, Ruth Chapman, International Journal of Antimicrobial Agents	2016	10
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective Rebekah H. Borse, Chloë Brown, N. Muszbek, Rheumatology and Therapy	2017	10

Page 1